Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Researchers discover how SHP-2 genetic defect may result in heart malformation

UNC researchers have discovered how the genetic defect underlying one of the most common congenital heart diseases keeps the critical organ from developing properly. According to the new research, mutations in a gene called SHP-2 distort the shape of cardiac muscle cells so they are unable to form a fully functioning heart.

7 Feb 2012

Aspirin and warfarin similar in preventing deaths and strokes in heart failure patients

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Chronic hyperglycemia may lead to cardiac damage

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests that hyperglycemia (high blood sugar) injures the heart, even in patients without a history of heart disease or diabetes.

3 Feb 2012

Anemia triples risk of dying within a year after having a stroke

Being anemic could more than triple your risk of dying within a year after having a stroke, according to research presented at the American Stroke Association's International Stroke Conference 2012.

3 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

$Heart failure associated with 30% increase in major fractures$

Heart failure associated with 30% increase in major fractures

Heart failure is associated with a 30 percent increase in major fractures and also identifies a high-risk population that may benefit from increased screening and treatment for osteoporosis, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Feb 2012

Medtronic initiates enrollment in IMPROVE HF Bridge Study

Medtronic, Inc. today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the implementation of evidence-based treatment guidelines among chronic heart failure patients post-hospital discharge.

From Medtronic 2 Feb 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Leading medical groups collaborate to ensure consistent, responsible uptake of TAVR

With the U.S. Food and Drug Administration's recent approval of transcatheter aortic valve replacement (TAVR) for patients with aortic valvular stenosis, the American College of Cardiology Foundation (ACCF), along with the American Association for Thoracic Surgery (AATS), the Society for Cardiovascular Angiography and Interventions (SCAI) and the Society of Thoracic Surgeons (STS), today released an expert consensus document to provide important guidance on its use.

1 Feb 2012

Initial data from Abiomed's Symphony safety trial on chronic heart failure

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that the initial clinical data from the safety study for Symphony was presented by Renzo Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 Annual Meeting in Fort Lauderdale, Florida.

1 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

Mayo Clinic Healthy Heart For Life! to be available online on Jan. 31

Heart disease is the nation's No. 1 killer for both men and women. But what's most astonishing is that almost 80 percent of heart disease is preventable, and even small lifestyle changes can have a big impact.

31 Jan 2012

Cedars-Sinai Heart Institute to mark National Go Red for Women Day

Hundreds of health care professionals at the Cedars-Sinai Heart Institute will wear red on Friday, Feb. 3, to mark National Go Red for Women Day. The group will meet at 9 a.m. for a group photo to demonstrate support for increased research on heart disease, the No. 1 killer in the U.S. For the first time the annual gathering this year will include blood pressure checks and heart disease risk assessments.

31 Jan 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012